Pulmonology

The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.

CHEST. After a moderate COPD event, treatment with TT within 30 days significantly reduced risk for exacerbation over 12 months vs treatment after 30 days.

AAFP Board Chair Sterling Ransone, Jr, MD, offers an Academy refresher on the annual push-back from patients that is so familiar to family medicine clinicians.

CHEST 2022. Tezepelumab significantly reduced AAER and improved lung function in patients taking 1, 2, or ≥3 long-acting β-agonists in addition to ICS.

The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.

The noninvasive, easily administered tool was able to predict at age 3 years children who would be diagnosed with asthma at age 5 years.

In-hospital pulmonary rehabilitation improves function and symptoms in COPD patients whether they are on triple therapy or not, a new study confirms.

Preventing viral infections with vaccination can keep the most vulnerable out of the hospital, reducing the risk of bacterial superinfections.

Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.

Lung airways were smaller in women than men, even among ever-smokers and never-smokers, according to large analysis.

A real-world study found that a delay in diagnosis of 1 year or more was particularly detrimental to patients with mild disease at time of diagnosis.

Additional research into tailored metered-dose inhaler education is needed, according to authors of a recent study.

For patients with chronic sinusitis, disease exacerbations often require use of antibiotics and steroids, in addition to medical office visits, all of which impact quality of life.

When asthma and COPD patients have a continuous relationship with a single provider, ED visits/hospitalizations go down, survival goes up, finds a new systematic review.

In persons with COPD, seasonal influenza and PPSV23 vaccines, separately or together, reduced the risk for COPD- and pneumonia-related hospitalizations.

Authors of this first study to compare the combinations head-to-head suggest that the glycopyrrolate combination is appropriate for long-term COPD management.

The FDA ban yesterday on Juul vaping devices and nicotine e-liquid pods drew praise from the American Medical Association, American Thoracic Society, American Lung Association, among others.

New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.

The Labcorp home test, available without a prescription, is delivered overnight and includes a return envelope. Results are available in 1-2 days.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.

Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.

ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.

ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.

ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.